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Abstract
Background: Preterm labour (PTL) is a major cause of neonatal mortality and morbidity, and oxytocin (OT) antagonists
are potential tocolytics. Atosiban (TRACTOCILE) is a mixed vasopressin V1A/OT antagonist registered for acute
treatment of PTL in Europe. Other off-label drugs have serious side effects. Barusiban is a selective OT antagonist which
has reached clinical development. A monkey model with OT-induced PTL was developed to compare barusiban and
atosiban. In addition, the feasibility for long-term treatment of PTL with barusiban was explored.
Methods: Conscious pregnant cynomolgus monkeys were monitored for intrauterine pressure (IUP). A sensor for IUP
was implanted into the amniotic cavity, and biopotential sensors for electromyogram were attached to the uterus. For
short-term experiments, individual low-dose OT infusions induced stable submaximal uterine contractions. Barusiban
and atosiban were administered either as intravenous bolus or infusion at high or low doses. For long-term treatment,
low-dose OT was infused daily for 3–6 hours to mimic PTL. In addition, continuous high-dose infusions of barusiban (150
μg kg-1 h-1) or fenoterol (3 μg kg-1 h-1) were administered.
Results: Contractions of 15–40 mmHg were induced with individual OT infusions at 5–90 mU kg-1 h-1, and no OT-
related desensitization occurred. Correlation was demonstrated between electromyograms and IUP curves. Barusiban
was well tolerated and its potency was 4 times higher than atosiban's. Barusiban and atosiban demonstrated >95%
efficacy. However, barusiban's duration of action was >13 hours (atosiban's 1–3 hours) and reversible with high-dose OT
in emergency situations. OT control and fenoterol-treated monkeys delivered preterm (ca. day 154) and showed an
increase in overall IUP. Barusiban-treated animals delivered normally following end of treatment (ca. day 163).
Conclusion: The presented telemetry model provides an excellent method to evaluate PTL drug candidates. OT
induced stable repetitive contractions and no desensitisation. Barusiban and atosiban demonstrated high efficacy and
rapid onset of action. Barusiban, a selective OT antagonist has higher potency and prolonged duration of action than
atosiban. Barusiban effectively suppressed IUP during daily OT-challenges, delayed labour, and prolonged monkeys'
pregnancy till term.
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Background
PTL is associated with neonatal morbidity and mortality
and represents an unmet clinical need. The incidence
ranges from 5–25 percent, shows an increasing trend, and
has a significant economic and social impact [1-7]. Many
preterm infants suffer from health problems, such as neu-
rosensory deficits, cerebral palsy, respiratory distress, gas-
trointestinal problems, growth deficits, and mental
retardation [8]. Endocrine OT from the hypothalamic-
pituitary axis and paracrine OT from the uterine/fetal
compartment are thought to drive labour and parturition
through its receptors [9-11]. Thus, OT antagonists are
potentially useful therapeutic agents to delay PTL and
delivery.
Atosiban (TRACTOCILE) is a mixed vasopressin V1A (pref-
erentially) and OT receptor antagonist [12]. It is the first
tocolytic specifically developed for management of PTL
and approved in Europe and many other countries [13].
Atosiban can be used for short-term treatment (typically
48 hours) to delay imminent preterm birth between 24
and 33 weeks of gestation. This provides the chance to
reduce respiratory distress syndrome by administration of
antenatal glucocorticoids and allows time for transfer in
utero to a neonatal intensive care unit. Most other tocolyt-
ics are used off-label, compromised by side effects for
mother and child, or offering limited efficacy.
Barusiban is a new long-acting OT receptor antagonist
developed for PTL. It is a cyclic heptapeptide and an ana-
logue of endogenous OT designed for longer duration of
action [12]. This could provide the convenience of less fre-
quent administration in the clinic. Barusiban has approx-
imately 300-fold greater affinity for the human cloned OT
receptor than for the V1A receptor, whereas atosiban binds
well to both receptors. In contractility studies with iso-
lated human myometrium, barusiban also demonstrates
more OT selective inhibitory effects [14]. It has reached
phase II of clinical development as a tocolytic.
Here, a non-human primate model for PTL is presented
that was developed to ensure full GLP compliance. Radio-
telemetry was employed to measure electromyograms
(EMG) and IUP, while remote dosing and blood sampling
was established. OT was used to induce stable uterine con-
tractions, and respective desensitisation was examined. A
detailed pharmacokinetic/pharmacodynamic (PK/PD)
comparison of barusiban with atosiban was performed in
terms of onset and duration of tocolysis, efficacy, and
potency. A rescue treatment was included to verify the
reversibility of tocolysis with OT. Finally, the feasibility of
long-term treatment with barusiban was demonstrated,
including a comparison with fenoterol, a β2 adrenergic
receptor agonist.
Methods
A telemetric-based model is presented for evaluation of
uterine contractions in pregnant cynomolgus monkeys
[15]. A pressure sensor was implanted into the amniotic
cavity and biopotential sensors were attached to the
uterus on gestational day (GD) 120 ± 3 (Figure 1). A
telemetry transmitter was placed in a subcuticular pocket
located in the flank. The model allows continuous moni-
toring of EMG and IUP as indicators of uterine activity.
Venous catheters were connected to the next room for
remote dosing and blood sampling for plasma analysis,
without disturbing the conscious animals or causing iatro-
genic influences on uterine contractions. OT was individ-
ually infused at 5–90 mU kg-1  h-1  to induce artificial
contractions of 15–40 mmHg that mimicked PTL (Figure
2). All protocols and procedures were approved by the
local Animal Care and Use Committee and according to
guidelines for laboratory animals.
During short-term treatment a total eight monkeys were
included, and each group consisted of three (or two) preg-
nant females [16]. The groups participated in up to four
phases of treatment that were separated by a 24–48 h
washout period. The first treatment phase generally
started on GD 128. OT control infusions were given at the
lowest dose required for stable and submaximal contrac-
tions in each individual female. The treatment phases
included: OT control, OT + barusiban, OT + atosiban, and
OT + barusiban and then escalating high-dose OT rescue
therapy (133–2000 mU kg-1 h-1). Dose levels of barusiban
and atosiban were 10–50 and 100–500 μg kg-1 (bolus)
and 2.5–150 and 50–250 μg kg-1 h-1 (infusion for 2–3 h),
respectively. These dose levels were selected to be in the
range of half-maximal to maximal efficacy, based on pre-
existing PK/PD data.
In long-term treatment, each group consisted of three (or
two) pregnant females [17]. The pregnant females were
dosed from ca. GD 141 to 163 or delivery, whichever
came first. OT was intravenously (IV) infused for 3–6 h
per day to simulate a situation of PTL with daily periods
of spontaneous contractions. Barusiban, fenoterol, or
saline (control animals) were administered by continuous
IV infusion for 24 h per day. The dose level for barusiban
(150 μg kg-1 h-1) was determined according to maximal
effects observed previously [16]. Atosiban was not further
investigated due to the limited number of animals. Fenot-
erol is approved for treatment of PTL and used in this
study as a comparative control. The dose level for fenote-
rol (3 μg kg-1 h-1) was based on the maximally effective
dose cited in the package insert, adjusted for the body
weight of monkeys.BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S15 http://www.biomedcentral.com/1471-2393/7/S1/S15
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Results
Method validation
The animals underwent surgery at about GD 120, and the
instrumentation for EMG, IUP, and dosing/blood sam-
pling was well tolerated; the monkeys recovered within
one week [15]. There was a good correlation between the
electrical bursts in the EMG and the increase in IUP (Fig-
ure 1). Typically contractions occurred every 3–6 min. The
highest spontaneous activity was observed in the first half
of the night with increasing intensity close to birth. Stable
contractions for comparison of the tocoloytics were
induced by individual infusion of 5–90 mU kg-1 h-1 OT
during the nights (Figure 2). No desensitisation of OT-
induced contractions was observed.
Short-term treatment
Following induction of stable contractions by OT, barusi-
ban or atosiban were administered as high- or low-dose
bolus or infusion [16]. Both antagonists showed an
immediate onset of action and full inhibitory efficacy
(Figure 3). However, barusiban's duration of action was
generally longer than 13–15 hours, while atosiban's effect
ceased within 1.5–3 hours (Table 1). The calculated
potency of barusiban was about four times higher than
the potency of atosiban.
In rescue treatments, the reversibility of barusiban's inhi-
bition of contractions was demonstrated. First, stable con-
tractions were established by low-dose OT infusion and
then a high-dose bolus of barusiban lead to full inhibition
of contractions. Finally, escalating high-dose OT infusion
reinstated the uterine contractions.
During the experiments a good EMG IUP correlation
could be shown. Following barusiban treatment and a
respective decrease in IUP, there was in parallel a
decreased electrical burst duration, an increased number
of bursts, and a decrease in the power density spectrum
(PDS) peak frequency (data not shown).
Long-term treatment
The animals were continuously infused with saline con-
trol, barusiban, or fenoterol [17]. During daily 3–6 hours
OT infusion, the control and fenoterol groups showed an
increase in IUP that was reduced in barusiban-treated ani-
mals (Figure 4). In 8/17 days and 11/17 days, the barusi-
ban group had statistically lower IUP than the control and
fenoterol groups, respectively.
During long-term IUP progression, barusiban was effec-
tive in maintaining low IUP during daily OT-challenges
(Figure 5). OT controls and the fenoterol group showed a
marked IUP increase 4–5 days prior to delivery which
occurred generally after 17 days of treatment. The barusi-
ban group continued pregnancy until the end of approxi-
mately 23 treatment days and delivered afterwards.
The basal overall IUP before the daily OT challenges was
unchanged during barusiban or fenoterol treatment com-
pared to control. During OT infusion, about a fourfold
increase occurred in overall IUP. In fenoterol-treated ani-
mals, the overall IUP increased approximately threefold.
However, in the barusiban group, there was only a 30 per-
cent rise in overall IUP.
Instrumented uterus and corresponding EMG and IUP corre- lation Figure 1
Instrumented uterus and corresponding EMG and 
IUP correlation. Top: Chronically instrumented uterus of 
a pregnant cynomolgus monkey in situ at GD 120, showing 
two bio-potential electrodes attached to the myometrium 
for measurement of electromyograms (EMG, scale: elec-
trodes are 1 cm apart) [15]. A tube was inserted into the 
amniotic cavity for registration of the respective intrauterine 
pressure (IUP). Bottom: Correlation between uterine EMG 
(blue) and IUP (red). Typical bursts and corresponding con-
tractions occur every 3–6 min. The highest spontaneous 
activity was observed in the night close to birth. Note the 
close relationship between bursts of electrical activity in the 
EMG and increases in IUP, here in the presence of OT infu-
sion.
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Discussion
The availability of a telemetric uterine contraction model
in preterm cynomolgus monkeys is an excellent reproduc-
tive tool for evaluation of tocolytic drug candidates [15].
The model does not interfere with maternal/fetal health
and is not impacted by iatrogenic disturbances or stress.
The surgery and instrumentation was well tolerated and
allows evaluation of uterine activity and PK/PD relation-
ships in response to exogenously administered drug can-
didates. OT was used as a means to induce stable PTL-like
contractions. Following OT infusion, neither short-term
nor long-term desensitisation occurred. Because of the
good EMG/IUP correlation, EMG may be an interesting
clinical tool for evaluation of uterine contractions in the
future.
The OT system is known to play a key role in the initiation
and maintenance of labour, including PTL [17]. In conse-
quence, OT antagonists are logical candidates for pharma-
cological management of PTL. The two OT receptor
antagonists, barusiban and atosiban, both have high effi-
cacy and rapid onset of action when evaluated for inhibi-
tion of OT-induced uterine contractions [16].
Furthermore, the inhibitory effects of barusiban were
reversible by administration of high-dose OT. This confers
control over the duration of inhibition, especially in the
case of emergency delivery by caesarean section. Barusi-
ban has higher potency and longer duration of action
than atosiban.
Barusiban is both safe and efficacious in reducing uterine
activity in response to daily OT challenge in a non-human
primate model that mimics long-term treatment in PTL.
Oxytocin-induced uterine contractions in cynomolgus monkeys Figure 2
Oxytocin-induced uterine contractions in cynomolgus monkeys. Individual infusion of 5–90 mU OT kg-1 h-1 induced 
stable uterine contractions of about 15–40 mmHg [15]. No short- or long-term desensitisation of OT-induced contractions 
was observed. On the background of these stable OT-induced contractions, different tocolytics have been evaluated in terms 
of their PK/PD characteristics. Here two monkeys were infused in parallel for about 11 hours during the night. The switch-off 
the lights in the evening (06:00 PM) and switch-on the lights (06:00 AM) is labelled by respective symbols.
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When administered by continuous infusion for the last ca.
3 weeks of pregnancy, barusiban prevented early birth
induced by OT and extended pregnancy to normal dura-
tion. Since neonatal survival rates improve three percent
with each day that pregnancy can be extended [18], this
might convey substantial socioeconomic benefit. This is
the first proof of principle that barusiban is effective for
long-term management of PTL-like contractions. Now,
clinical trials have to verify barusiban's effectiveness com-
pared to its effect on OT-induced PTL in non-human pri-
mates.
Conclusion
Taken together, the presented model is useful for PK/PD
evaluation of drug candidates intended to be used in PTL.
Continuous low-dose OT infusions induce stable uterine
contractions. A good correlation between EMG and IUP
was observed.
Barusiban suppressed OT-induced PTL-like uterine con-
tractions with immediate onset of action and high effi-
cacy. Compared with atosiban, it had a higher potency
and longer duration of action. Barusiban's inhibition
could be reversed by high-dose OT.
During long-term treatment, barusiban reduced IUP in
OT-challenged monkeys; it delayed the onset of labour
and lead to a prolonged pregnancy. Barusiban is suggested
as a safe and effective tocolytic for acute and maintenance
treatment.
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Intrauterine pressure progression during long-term treat- ment Figure 5
Intrauterine pressure progression during long-term 
treatment. Barusiban inhibited OT-induced increases in 
IUP in near-term pregnant monkeys (GD ca. 141 to 163 or 
delivery) [17]. In general, IUP was lowest throughout the last 
about three weeks of pregnancy in barusiban-treated females 
(150 μg kg-1 h-1, orange), compared to OT controls (green), 
or fenoterol-treated females (3 μg kg-1 h-1, yellow). Barusiban 
was particularly effective in maintaining low IUP near the end 
of gestation. OT control and fenoterol-treated animals gave 
preterm birth, barusiban-treated animals continued preg-
nancy till term, when the treatment was stopped, and the 
mothers delivered normally. Data shown are means ± SEM 
for n = 3 (controls, barusiban) or n = 2 (fenoterol).
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Table 1: Summary of barusiban and atosiban PK/PD characteristics
Pharmacodynamics (PD) Barusiban Atosiban
Onset of action, hours ≤0.5–1.5 ≤0.5–1.0
Efficacy (decrease in IUP), % ≤98 ≤96
Duration of action, hours > 13–15 1–3
Potency (IC50), ng/ml 12.7 47.4
Pharmacokinetics (PK) Barusiban Atosiban
Half-life, hours 1.46–2.57 0.46–0.66
Clearance, ml h-1 kg-1 25–66 539–936
Distribution, ml kg-1 70–159 359–640
The values in the table represent the overall results obtained for barusiban and atosiban given IV as high- or low-dose bolus or infusion, respectively 
to pregnant cynomolgus monkeys [16]. The plasma samples were analysed with liquid chromatography and tandem mass-spectroscopy.BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S15 http://www.biomedcentral.com/1471-2393/7/S1/S15
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